Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Olympus ( (JP:7733) ) has shared an announcement.
Olympus reported that its fiscal 2026 results modestly exceeded prior guidance, with revenue rising to ¥1.01 trillion and all major profit indicators coming in above earlier forecasts. The company noted that these figures reflect continuing operations, following the earlier classification of its Orthopedic Business as a discontinued operation.
The outperformance was driven mainly by the Gastrointestinal Solutions business, where strong promotional efforts in North America boosted sales of endoscopes featuring Extended Depth of Field technology and the EU-ME3 endoscopic ultrasound system. Additional gains from the sale of overseas real estate further lifted profitability, underscoring the resilience of Olympus’s core medical portfolio and providing a positive signal for investors focused on its endoscopy-led growth strategy.
The most recent analyst rating on (JP:7733) stock is a Hold with a Yen1700.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.
More about Olympus
Olympus Corporation is a Japanese medical technology company listed on the Tokyo Stock Exchange that focuses on endoscopic and other imaging-based solutions for healthcare. The company has a strong presence in gastrointestinal diagnostics and therapeutic devices, with a particular emphasis on advanced endoscope technologies and systems tailored to major markets such as North America.
Average Trading Volume: 6,650,062
Technical Sentiment Signal: Sell
Current Market Cap: Yen1730B
For an in-depth examination of 7733 stock, go to TipRanks’ Overview page.